Accessibility Menu
Htg Molecular Diagnostics logo

Htg Molecular Diagnostics(OTC) HTGMQ

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-99%
1 Month+0%
$0.00
+0.00%
+0.00Today
Htg Molecular Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-01
Htg Molecular Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99%USD 0.002026-08-24
1 month+0%USD 0.002026-07-14
3 month-99%USD 0.002026-06-01
Year to date-99%USD 0.002025-12-31
1 year-99%USD 0.002025-08-27
3 year-100%USD 0.302023-09-01
5 year-100%USD 80.762021-09-02
Since inception-100%USD 2,509.202015-05-07

Htg Molecular Diagnostics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.21M

Net Income (TTM)

-$20.15M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

83.82 (High)

Price

$0.00

Volume

1,111

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 31, 2026

HTGMQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Htg Molecular Diagnostics

HTG Molecular Diagnostics, Inc. is a life sciences company based in Tucson, Arizona, focused on advancing precision medicine. The company offers a comprehensive suite of products, including specialized instruments, assay kit consumables, and software solutions designed to automate sample processing and accurately profile various molecular targets.

Products and Services
  • HTG Transcriptome Panel for comprehensive gene expression analysis
  • HTG EdgeSeq precision immuno-oncology panel for targeted cancer therapies
  • HTG EdgeSeq miRNA whole-transcriptome assay for miRNA profiling
Growth Outlook
  • Recent partnerships with biopharmaceutical companies enhance market reach
  • Expansion into European markets increases potential customer base
  • Innovative product development aims to capture emerging market trends
Financial Highlights
  • Q1 2023 revenue of $1,032,510, a decrease from Q4 2022
  • Trailing twelve months (TTM) gross profit margin of 28.18%
  • Current ratio of 1.89 indicates strong short-term financial health
HTG Molecular Diagnostics, Inc. is positioned in the medical diagnostics and research industry, providing essential tools for precision medicine. The company's diverse product offerings cater to a wide range of clients, including biopharmaceutical companies and academic research centers. Recent financial data indicates a revenue of $1,032,510 for Q1 2023, reflecting a decrease from the previous quarter, which may raise questions about short-term performance. However, the TTM gross profit margin of 28.18% suggests potential for profitability as the company continues to innovate and expand its product line. The current ratio of 1.89 indicates that HTG Molecular Diagnostics has sufficient short-term assets to cover its liabilities, which is a positive sign for potential investors. The company's strategic partnerships and market expansion efforts are expected to drive future growth, making it an intriguing option for those interested in the life sciences sector.
AI Generated • Aug 22, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

53

CEO

John L. Lubniewski

Website

www.htgmolecular.com

Headquarters

Tucson, AZ 85706, US

HTGMQ Financials

Key Financial Metrics (TTM)

Gross Margin

28.18%

Operating Margin

-327.19%

Net Income Margin

-339.20%

Return on Equity

-273.49%

Return on Capital

-151.55%

Return on Assets

-121.47%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.21M

Volume

1.11K

Avg. Volume

184.531

Financials (TTM)

Gross Profit

$1.35M

Operating Income

-$19.59M

EBITDA

-$18.91M

Operating Cash Flow

-$16.83M

Capital Expenditure

-$20.87K

Free Cash Flow

-$16.85M

Cash & ST Invst.

$6.56M

Total Debt

$3.98M

Htg Molecular Diagnostics Performance Analysis

Htg Molecular Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 8,906,828N/A
20222022-12-31USD 6,366,220-28.5%
Htg Molecular Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-3025.9%
Q32022-09-30-16.1%
Q42022-12-3195.0%
Q12023-03-31-57.7%
Htg Molecular Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -29.66N/A
20222022-12-31USD -24.28-18.1%
Htg Molecular Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-3034.0%
Q32022-09-3023.5%
Q42022-12-3156.8%
Q12023-03-31-7.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2023YOY CHG

Revenue

$1.03M

-12.8%

Gross Profit

-$117.10K

-135.5%

Gross Margin

-11.34%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

53

N/A

Net Income

-$5.05M

+22.2%

EBITDA

-$4.83M

+20.4%

Quarterly Fundamentals

Name
Q1 2023YOY CHG

Total Cash

$6.56M

-69.6%

Total Debt

$3.98M

-58.0%

Accounts Receivable

$1.13M

+51.1%

Inventory

$654.92K

-67.6%

Long Term Debt

$423.24K

-89.5%

Short Term Debt

$3.56M

-34.4%

Return on Assets

-1.21%

N/A

Return on Invested Capital

-2.19%

N/A

Free Cash Flow

-$4.37M

+26.5%

Operating Cash Flow

-$4.36M

+26.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIOCQBiocept, Inc.
$0.00+0.00%
CRFTFBC Craft Supply Co. Ltd.
$0.00+0.00%
CLVRClever Leaves Holdings Inc.
$0.00+0.00%
HLTHQCue Health Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.34-0.10%
INTCIntel
$95.80+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.37+0.00%
NOKNokia
$10.03+0.03%

Questions About HTGMQ

What is the current price of Htg Molecular Diagnostics?

Htg Molecular Diagnostics is trading at $0.00 per share.

What is the 52-week range for Htg Molecular Diagnostics?

Over the past 52 weeks, Htg Molecular Diagnostics has traded between $0.00 and $0.00.

How much debt does Htg Molecular Diagnostics have?

As of the most recent reporting period, Htg Molecular Diagnostics reported total debt of $8.80M.

How much cash does Htg Molecular Diagnostics have on hand?

Htg Molecular Diagnostics reported $12.21M in cash and cash equivalents in its most recent financial results.

What is Htg Molecular Diagnostics’s dividend yield?

Htg Molecular Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services